Published in Clin Cancer Res on July 20, 2011
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet (2014) 1.16
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics (2014) 1.00
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One (2012) 0.99
MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res (2013) 0.98
Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol (2013) 0.96
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics (2014) 0.93
miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget (2016) 0.91
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer (2014) 0.87
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. PLoS One (2012) 0.86
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget (2015) 0.84
Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease. Public Health Genomics (2014) 0.84
Identification of cisplatin-regulated metabolic pathways in pluripotent stem cells. PLoS One (2013) 0.83
Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients. Sci Rep (2015) 0.82
Localization of association signal from risk and protective variants in sequencing studies. Front Genet (2012) 0.82
Establishment & characterization of lymphoblastoid cell lines from patients with multiple primary neoplasms in the upper aero-digestive tract & healthy individuals. Indian J Med Res (2012) 0.81
Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair. Int J Mol Cell Med (2012) 0.80
Prediction of a time-to-event trait using genome wide SNP data. BMC Bioinformatics (2013) 0.79
In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics (2015) 0.79
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One (2013) 0.78
Integrative gene set analysis: application to platinum pharmacogenomics. OMICS (2013) 0.78
The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer. J Ovarian Res (2015) 0.78
Computational discovery of transcription factors associated with drug response. Pharmacogenomics J (2015) 0.75
The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy. Transl Oncol (2016) 0.75
DAPK3 suppresses acini morphogenesis and is required for mouse development. Mol Cancer Res (2014) 0.75
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. OMICS (2017) 0.75
Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci (2017) 0.75
Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population. Int J Clin Exp Med (2015) 0.75
Germline genetic variants and lung cancer survival in African Americans. Cancer Epidemiol Biomarkers Prev (2017) 0.75
GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin. PLoS One (2017) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Genetic analysis of genome-wide variation in human gene expression. Nature (2004) 27.28
MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol (2010) 26.41
Genetics of gene expression and its effect on disease. Nature (2008) 21.35
A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 18.98
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet (2008) 5.08
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res (2004) 1.91
ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol Cell Biol (1998) 1.88
Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res (2010) 1.87
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One (2009) 1.75
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med (2008) 1.57
Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet (2006) 1.50
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2008) 1.46
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.32
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet (2007) 1.32
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res (2001) 1.22
Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer (2009) 1.21
Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest (2005) 1.20
DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol (2002) 1.17
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol (2005) 1.14
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol (2010) 1.14
Platinum pathway. Pharmacogenet Genomics (2009) 1.12
Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer (2006) 1.11
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics (2008) 1.05
Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev (2010) 1.04
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics (2009) 1.04
DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol (2004) 1.03
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol (2006) 1.00
Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2010) 1.00
Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol (2008) 1.00
Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2010) 0.99
Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol (2010) 0.96
ZIPK: a unique case of murine-specific divergence of a conserved vertebrate gene. PLoS Genet (2007) 0.92
Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol (2008) 0.84
A quality control algorithm for filtering SNPs in genome-wide association studies. Bioinformatics (2010) 0.83
HMDB: the Human Metabolome Database. Nucleic Acids Res (2007) 13.38
HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res (2008) 11.23
Duration of red-cell storage and complications after cardiac surgery. N Engl J Med (2008) 10.04
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet (2004) 4.95
Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med (2006) 4.59
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Nonparametric tests of association of multiple genes with human disease. Am J Hum Genet (2005) 2.87
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
The Drosophila nuclear receptor e75 contains heme and is gas responsive. Cell (2005) 2.73
Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol (2009) 2.64
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet (2002) 2.51
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 2.50
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy (2011) 2.47
The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest (2004) 2.44
Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg (2006) 2.42
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer (2009) 2.32
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet (2004) 2.31
Lung cancer in China: challenges and interventions. Chest (2013) 2.31
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics (2013) 2.27
IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet (2008) 2.27
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood (2007) 2.25
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Detecting bacteria and determining their susceptibility to antibiotics by stochastic confinement in nanoliter droplets using plug-based microfluidics. Lab Chip (2008) 2.11
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev (2007) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. Clin Chem (2006) 2.00
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc (2005) 2.00
Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg (2007) 1.99
Perioperative management and treatment for complications during and after peroral endoscopic myotomy (POEM) for esophageal achalasia (EA) (data from 119 cases). Surg Endosc (2012) 1.98
Methods to impute missing genotypes for population data. Hum Genet (2007) 1.98
The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.96
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology (2004) 1.95
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res (2007) 1.91
Identification of bacteria using tandem mass spectrometry combined with a proteome database and statistical scoring. Anal Chem (2004) 1.89
The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol (2008) 1.88
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet (2011) 1.88
Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res (2010) 1.87
Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol (2002) 1.86
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84